Landos Biopharma, Inc.

Quarterly Report for period ending 2023-09-30

Quarterly Report for period ending 2023-06-30

Quarterly Report for period ending 2023-03-31

Annual Report for period ending 2022-12-31

Quarterly Report for period ending 2022-09-30

Quarterly Report for period ending 2022-06-30

Quarterly Report for period ending 2022-03-31

Annual Report for period ending 2021-12-31

Quarterly Report for period ending 2021-09-30

Quarterly Report for period ending 2021-06-30

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Annual report to security holders

Notice of Effectiveness

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

Notice of Effectiveness

Certification by an exchange approving securities for listing

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

Bassaganya-Riera Josep: Major Shareholders

Batycky Alka: Initial statement of beneficial ownership of securities

Batycky Alka: Statement of changes in beneficial ownership of securities

Girao Tiago: Statement of changes in beneficial ownership of securities

MAYLEBEN TIMOTHY M: Statement of changes in beneficial ownership of securities

Garabedian Christopher Nishan: Statement of changes in beneficial ownership of securities

Callori Fred: Statement of changes in beneficial ownership of securities

Adsett Roger: Statement of changes in beneficial ownership of securities

PERCEPTIVE ADVISORS LLC: Major Shareholders

Xontogeny, LLC: Major Shareholders

Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Registration statement for specified transactions by certain issuers

Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Registration statement for specified transactions by certain issuers

Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Prospectus filed pursuant to Rule 424(b)(4)

General form of registration statement for all companies including face-amount certificate companies

General form of registration statement for all companies including face-amount certificate companies

General form of registration statement for all companies including face-amount certificate companies

Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

Definitive proxy statements

Preliminary proxy statement not related to a contested matter or merger/acquisition

Definitive proxy statements

Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.